Skip to main content
Clinical Trials/NCT03983889
NCT03983889
Unknown
Not Applicable

The Effect and Safety of Different Sedation Strategies for Diagnostic Bronchoscopy

Changhai Hospital1 site in 1 country200 target enrollmentJune 17, 2019

Overview

Phase
Not Applicable
Intervention
Midazolam
Conditions
Bronchoscopy
Sponsor
Changhai Hospital
Enrollment
200
Locations
1
Primary Endpoint
Cough score
Last Updated
6 years ago

Overview

Brief Summary

Diagnostic bronchoscopy is an invasive procedure performed to diagnose respiratory diseases. But pain has been complained by most of the patients receiving such procedures. Sedation or anesthesia was required by both of the patients and bronchoscopists. Unfortunately, no consensus has been made upon the sedation strategies. Multiple sedation approaches have been applied, such as midazolam and fentanyl, remifentanil and propofol, dexmedetomidine and propofol. The present study was designed to compare these protocols in sedation for diagnostic bronchoscopy.

Registry
clinicaltrials.gov
Start Date
June 17, 2019
End Date
December 31, 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jia-feng Wang

Clinical Professor

Changhai Hospital

Eligibility Criteria

Inclusion Criteria

  • Scheduled for flexible diagnostic bronchoscopy
  • Adult patients aged 18 to 65 years
  • American Society of Anesthesiologists (ASA) Physical Status Classification I-II
  • BMI 18.5-25kg/m2
  • Subjects provide informed consent

Exclusion Criteria

  • Severe airway obstruction
  • Coagulation disorder
  • Repeat bronchoscopy (more than 3 times)
  • Severe liver and renal dysfunction
  • Cardiovascular and cerebrovascular diseases
  • Pregnancy
  • Chronic opioid user
  • Drug abusers or addicts

Arms & Interventions

F

Sedated with intravenous midazolam (0.03mg/kg) and fentanyl (1μg/kg) for induction and maintenance

Intervention: Midazolam

F

Sedated with intravenous midazolam (0.03mg/kg) and fentanyl (1μg/kg) for induction and maintenance

Intervention: Fentanyl

DR

Sedated with intravenous midazolam (0.03mg/kg), dexmedetomidine (0.5-1μg/kg for induction+0.5-0.7μg/kg/h for maintenance) and remifentanil (plasma concentration 2.0-2.5ng/ml) for induction and maintenance

Intervention: Midazolam

DR

Sedated with intravenous midazolam (0.03mg/kg), dexmedetomidine (0.5-1μg/kg for induction+0.5-0.7μg/kg/h for maintenance) and remifentanil (plasma concentration 2.0-2.5ng/ml) for induction and maintenance

Intervention: Dexmedetomidine

DR

Sedated with intravenous midazolam (0.03mg/kg), dexmedetomidine (0.5-1μg/kg for induction+0.5-0.7μg/kg/h for maintenance) and remifentanil (plasma concentration 2.0-2.5ng/ml) for induction and maintenance

Intervention: Remifentanil

DF

Sedated with intravenous midazolam (0.03mg/kg), dexmedetomidine (0.5-1μg/kg for induction+0.5-0.7μg/kg/h for maintenance) and fentanyl (1μg/kg) for induction and maintenance

Intervention: Midazolam

DF

Sedated with intravenous midazolam (0.03mg/kg), dexmedetomidine (0.5-1μg/kg for induction+0.5-0.7μg/kg/h for maintenance) and fentanyl (1μg/kg) for induction and maintenance

Intervention: Fentanyl

DF

Sedated with intravenous midazolam (0.03mg/kg), dexmedetomidine (0.5-1μg/kg for induction+0.5-0.7μg/kg/h for maintenance) and fentanyl (1μg/kg) for induction and maintenance

Intervention: Dexmedetomidine

PR

Sedated with intravenous midazolam (0.03mg/kg), propofol (plasma concentration 1.0-2.0ng/ml) and remifentanil (plasma concentration 2.0-2.5ng/ml) for induction and maintenance

Intervention: Midazolam

PR

Sedated with intravenous midazolam (0.03mg/kg), propofol (plasma concentration 1.0-2.0ng/ml) and remifentanil (plasma concentration 2.0-2.5ng/ml) for induction and maintenance

Intervention: Remifentanil

PR

Sedated with intravenous midazolam (0.03mg/kg), propofol (plasma concentration 1.0-2.0ng/ml) and remifentanil (plasma concentration 2.0-2.5ng/ml) for induction and maintenance

Intervention: Propofol

Outcomes

Primary Outcomes

Cough score

Time Frame: From the completion of local anesthesia with lidocaine to the completion of bronchoscopy procedure, assessed up to 2 hours

Cough score across the procedure will be classified into 4 degree (1-4) as follows. 1 = none, 2 = one gag or cough only, 3 = \>1 gag or cough, but acceptable conditions, 4 = unacceptable conditions

Secondary Outcomes

  • Amount of the rescue use of propofol(After sedation induction, assessed up to 2 hours)
  • Recovery time(After termination of the sedation medication, assessed up to 2 hours)
  • Prevalence of the side effects of respiratory and circulatory system(Across the sedation duration, assessed up to 2 hours)
  • Body movement(From the completion of local anesthesia with lidocaine to the completion of bronchoscopy procedure, assessed up to 2 hours)
  • Satisfaction score of the patients and bronchoscopists(Across the procedure, assessed up to 2 hours)

Study Sites (1)

Loading locations...

Similar Trials